Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
RBC Capital cut its target to $30 from $35 while keeping an ‘Outperform’ rating, according to The Fly.…
Roche to Present New Elecsys Alzheimer’s Blood Test Data at AAIC 2026
Roche announced it will present 18 oral and poster presentations from its Alzheimer’s disease portfolio at the Alzheimer’s…